Biosynthesis and Characterization of Vosoritide by Escherichia coli
Pharmaceutical Fronts · 01.09.2025 · 07 (03) · e245-e257
DOI: 10.1055/a-2647-7793 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Fronts, erschienen am 01.09.2025. Verfasst von Shuaiyi Huang und 6 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Vosoritide is a therapeutic peptide that promotes skeletal growth by targeting the NPR-B receptor and was approved in 2021 for the treatment of achondroplasia. However, its high production cost poses a considerable economic burden on patients, limiting its widespread use. This study aims to establish an efficient and cost-effective biosynthetic process for the production of Vosoritide using Escherichia coli. In this work, Vosoritide was expressed as inclusion bodies (IBs) in E. coli BL21 (DE3) via a gp55 fusion strategy. Downstream processes, including fermentation, HCl-induced acidic cleavage of IBs, pH-dependent protein precipitation, as well as the performing conditions of the ion-exchange chromatography and reverse-phase chromatography, were optimized. The analysis methods included sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), high-performance liquid chromatography (HPLC), and liquid chromatography-tandem mass spectrometry. Cyclic guanosine monophosphate (cGMP) assays were conducted to assess the biological activity of the protein in NIH3T3 cells. Vosoritide was obtained at 1.3 g per liter of fermentation broth with a purity exceeding 99%. The peptide's primary structure, molecular weight, and disulfide bond integrity were also confirmed through mass spectrometry and peptide mapping. The purified Vosoritide stimulated cGMP production in NIH3T3 cells with a half-maximal effective concentration (EC50) of 0.37 nmol/L. In conclusion, this study provided a scalable, high-yield production method for Vosoritide that yields Vosoritide with pharmaceutical-grade purity and activity, holding significant potential for manufacturing a cost-effective biosimilar with broader clinical accessibility.
Zitieren
APA
Huang, S., Hu, X., Luo, T., Xu, J., Duan, Y., Lu, J., & Feng, J. (2025). Biosynthesis and Characterization of Vosoritide by Escherichia coli. Pharmaceutical Fronts, 07(03), e245-e257. https://doi.org/10.1055/a-2647-7793
Vancouver
Huang S, Hu X, Luo T, Xu J, Duan Y, Lu J, et al. Biosynthesis and Characterization of Vosoritide by Escherichia coli. Pharmaceutical Fronts. 2025;07(03):e245-e257. doi:10.1055/a-2647-7793
BibTeX
@article{Huang2025,
author = {Huang, Shuaiyi and Hu, Xiaoyue and Luo, Tao and Xu, Jun and Duan, Yu and Lu, Jianguang and Feng, Jun},
title = {Biosynthesis and Characterization of Vosoritide by Escherichia coli},
journal = {Pharmaceutical Fronts},
year = {2025},
volume = {07},
number = {03},
pages = {e245--e257},
doi = {10.1055/a-2647-7793}
}
EUVIMED